

Corresponding author(s):	Erle S. Robertson
Last updated by author(s):	Apr 23, 2020

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Software and code

Policy information about availability of computer code

Data collection

The protocols have been clearly described in the "Methods" section, including Cytation 5 Multi-Mode Reader (BioTek), FACSCalibur System (Becton Dickinson), Orbitrap Fusion System (Thermo Fisher Scientific), StepOne Real-Time PCR System (Thermo Fisher Scientific), Odyssey Scanner (LiCor Inc.).

Data analysis

The analysis pipelines are introduced in the "Methods" section, which refer to FlowJo V10 (TreeStar), MaxQuant (Version 1.5.3.30), Odyssey Infrared Imaging System (Version 3.0.16), GraphPad Prism (Version 6.01).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data in this study have been included in this manuscript or submitted in to public datasets. Please refer to the "Data and materials availability" section.

Field-spe	ecific r	eporting		
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
\(\sum_{\text{life sciences}}\)		Behavioural & social sciences		
For a reference copy of t	the document wi	th all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	nces st	tudy design		
All studies must dis	sclose on the	se points even when the disclosure is negative.		
Sample size	Sample-size v	-size was calculated based on the similar study in the field and stated in the figure legends or the methods section.		
Data exclusions	No data was	excluded for analysis.		
Replication	The replication	replication numbers were indicated in the figure legends.		
Randomization	Animals were	e randomly assigned for the different treatment in this study.		
Blinding	The investiga	The investigators were not blinded to group allocation during data collection and analysis.		
Reportin	g for s	specific materials, systems and methods		
		rs about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp				
n/a Involved in th	•	n/a Involved in the study		
☐ X Antibodies				
Eukaryotic	ryotic cell lines			
	Palaeontology MRI-based neuroimaging			
	nd other organi			
Human res	search participa	ints		
Cillical dat	Ld			
Antibodies				
Antibodies used		The detailed information of these antibodies has been introduced in this study and supplementary table 1.		
Validation		All of the used antibodies are from the indicated commercial sources in the supplementary table 1.		
Eukaryotic c	ell lines			
Policy information	about <u>cell lin</u>	<u>es</u>		
Cell line source(s)	The source of all of the cell lines are described in the supplementary table 1.		
Authentication		All of the cells were authenticated by the provider or our previous studies. No additional authentication was conducted in this study.		
Mycoplasma con	tamination	The cell lines were tested to be mycoplasma-free.		
Commonly misid (See <u>ICLAC</u> register		No commonly misidentified lines were used.		
Animals and	other o	rganisms		
		s involving animals: ARRIVE guidelines recommended for reporting animal research		

NOD.CB17-Prkdcscid/J (NOD/SCID) mice

Laboratory animals

Wild animals	The study did not involve wild animals.
Field-collected samples	The study did not involve samples collected from the field.
Ethics oversight	These experiments were conducted under the supervision and management of the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC) with approved protocol #804549.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about studies involving human research participants

Human peripheral blood mononuclear cells (PBMCs), normal T-cells and B-cells were provided by the University of Pennsylvania Human Immunology Core (HIC), and Patient-derived xenografts (PDXs) were obtained from Fox Chase Cancer Center (FCCC).

Recruitment These samples were from different unidentified and healthy donors with written, informed consent.

All the procedures were approved by the Institutional Review Board (IRB) at the University of Pennsylvania or the Fox Chase Ethics oversight Cancer Center.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Population characteristics

Plots

Confirm that:

The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

0,	
Sample preparation	The detailed protocol was described in the "Methods" section.
Instrument	FACSCalibur system (Becton Dickinson).
Software	FlowJo software V10 (TreeStar).
Cell population abundance	At least 10000 cells were collected per sample.
Gating strategy	Only living cells were used for gating.
Tick this box to confirm the	hat a figure exemplifying the gating strategy is provided in the Supplementary Information.